In glioblastoma, however, we have not detected any remarkable effects of SOX1 silencing on difference in the expression of β-catenin and its downstream target MYC at a cellular level in vitro, in tumors in vivo, as well as in clinical biopsies. Here, SOX1 is linked to glioblastoma.